Barron's reports that growth in Johnson & Johnson's pharmaceutical business masked a stumble in MedTech.
Barron's reports that Johnson & Johnson raised its earnings guidance, while growth in its pharmaceutical business masked a stumble in MedTech.
51.3K
3 Sources, first seen ago
@barronsonlineJohnson & Johnson Hikes Earnings Guidance but Pharma Growth Masks a MedTech Stumble https://trib.al/3jACAYn
@CNBCJ&J beats earnings estimates; Middle East conflict weighs on medical-device sales https://www.cnbc.com/2026/10/13/jnj-earnings-q3-2026.html?taid=6ace0eb2d9017d000112fac9&utm_campaign=trueanthem&utm_content=main&utm_medium=social&utm_source=twitter
@businessJohnson & Johnson raises its profit guidance, driven by demand for newer drugs in cancer and autoimmune diseases https://www.bloomberg.com/news/articles/2026-10-13/j-j-lifts-earnings-outlook-after-jump-in-quarterly-drug-sales?taid=6ace27d79334400001312871&utm_campaign=trueanthem&utm_content=business&utm_medium=social&utm_source=twitter@barronsonlineJohnson & Johnson Hikes Earnings Guidance but Pharma Growth Masks a MedTech Stumble https://trib.al/3jACAYn@CNBCJ&J beats earnings estimates; Middle East conflict weighs on medical-device sales https://www.cnbc.com/2026/10/13/jnj-earnings-q3-2026.html?taid=6ace0eb2d9017d000112fac9&utm_campaign=trueanthem&utm_content=main&utm_medium=social&utm_source=twitter@businessJohnson & Johnson raises its profit guidance, driven by demand for newer drugs in cancer and autoimmune diseases https://www.bloomberg.com/news/articles/2026-10-13/j-j-lifts-earnings-outlook-after-jump-in-quarterly-drug-sales?taid=6ace27d79334400001312871&utm_campaign=trueanthem&utm_content=business&utm_medium=social&utm_source=twitter@barronsonlineJohnson & Johnson Hikes Earnings Guidance but Pharma Growth Masks a MedTech Stumble https://trib.al/3jACAYn@CNBCJ&J beats earnings estimates; Middle East conflict weighs on medical-device sales https://www.cnbc.com/2026/10/13/jnj-earnings-q3-2026.html?taid=6ace0eb2d9017d000112fac9&utm_campaign=trueanthem&utm_content=main&utm_medium=social&utm_source=twitter@businessJohnson & Johnson raises its profit guidance, driven by demand for newer drugs in cancer and autoimmune diseases https://www.bloomberg.com/news/articles/2026-10-13/j-j-lifts-earnings-outlook-after-jump-in-quarterly-drug-sales?taid=6ace27d79334400001312871&utm_campaign=trueanthem&utm_content=business&utm_medium=social&utm_source=twitter@barronsonlineJohnson & Johnson Hikes Earnings Guidance but Pharma Growth Masks a MedTech Stumble https://trib.al/3jACAYn@CNBCJ&J beats earnings estimates; Middle East conflict weighs on medical-device sales https://www.cnbc.com/2026/10/13/jnj-earnings-q3-2026.html?taid=6ace0eb2d9017d000112fac9&utm_campaign=trueanthem&utm_content=main&utm_medium=social&utm_source=twitter@businessJohnson & Johnson raises its profit guidance, driven by demand for newer drugs in cancer and autoimmune diseases https://www.bloomberg.com/news/articles/2026-10-13/j-j-lifts-earnings-outlook-after-jump-in-quarterly-drug-sales?taid=6ace27d79334400001312871&utm_campaign=trueanthem&utm_content=business&utm_medium=social&utm_source=twitter—
Not ranked yet
—
Not ranked yet
